Below are the most recent publications written about "Product Surveillance, Postmarketing" by people in Profiles.
-
Crisafulli S, Sultana J, Ingrasciotta Y, Addis A, Cananzi P, Cavagna L, Conter V, D'Angelo G, Ferrajolo C, Mantovani L, Pastorello M, Scondotto S, Trifirò G. Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. Expert Opin Drug Saf. 2019 Jun; 18(6):497-509.
-
Platt R, Brown JS, Robb M, McClellan M, Ball R, Nguyen MD, Sherman RE. The FDA Sentinel Initiative - An Evolving National Resource. N Engl J Med. 2018 Nov 29; 379(22):2091-2093.
-
Kata V, Novitch MB, Jones MR, Anyama BO, Helander EM, Kaye AD. Opioid addiction, diversion, and abuse in chronic and cancer pain. Curr Opin Support Palliat Care. 2018 06; 12(2):124-130.
-
Deery SE, Shean KE, Pothof AB, O'Donnell TFX, Dalebout BA, Darling JD, Bodewes TCF, Schermerhorn ML. Three-Year Results of the Endurant Stent Graft System Post Approval Study. Ann Vasc Surg. 2018 Jul; 50:202-208.
-
Jones WS, Krucoff MW, Morales P, Wilgus RW, Heath AH, Williams MF, Tcheng JE, Marinac-Dabic JD, Malone ML, Reed TL, Fukaya R, Lookstein RA, Handa N, Aronow HD, Bertges DJ, Jaff MR, Tsai TT, Smale JA, Zaugg MJ, Thatcher RJ, Cronenwett JL. Registry Assessment of Peripheral Interventional Devices (RAPID): Registry assessment of peripheral interventional devices core data elements. J Vasc Surg. 2018 02; 67(2):637-644.e30.
-
Zeitoun JD, Ross JS, Atal I, Vivot A, Downing NS, Baron G, Ravaud P. Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study. BMJ Open. 2017 12 21; 7(12):e018587.
-
Solotke MT, Dhruva SS, Downing NS, Shah ND, Ross JS. New and incremental FDA black box warnings from 2008 to 2015. Expert Opin Drug Saf. 2018 Feb; 17(2):117-123.
-
Toh S, Reichman ME, Graham DJ, Hampp C, Zhang R, Butler MG, Iyer A, Rucker M, Pimentel M, Hamilton J, Lendle S, Fireman BH. Prospective Postmarketing Surveillance of Acute Myocardial Infarction in New Users of Saxagliptin: A Population-Based Study. Diabetes Care. 2018 01; 41(1):39-48.
-
Vaduganathan M, DeFilippis EM, Fonarow GC, Butler J, Mehra MR. Postmarketing Adverse Events Related to the CardioMEMS HF System. JAMA Cardiol. 2017 11 01; 2(11):1277-1279.
-
Resnic FS, Majithia A. Postmarket medical device safety: moving beyond voluntary reporting. BMJ Qual Saf. 2018 03; 27(3):174-175.